跳到正文
原文
Medical Xpress·· 2026-10-10AI 评分41

实验室培养的血管揭示早衰症(HGPS)中不同细胞的作用

Lab-grown blood vessels reveal roles of different cells in rapid-aging disease

AI 导读

杜克大学团队用三层组织工程血管模型揭示,早衰症(HGPS)中平滑肌细胞促成胶原堆积、内皮细胞促成炎症,带HGPS突变的成纤维细胞显著增加细胞外基质改变和纤维化信号。用CRISPR校正突变后,工程血管中多数疾病特征向健康水平恢复。

正文
Lab Grown Blood Vessels Reveal Role of Different Cells in Rapid-Aging Disease
A tri-layer tissue-engineered blood vessel (TEBV) cross section showing fibroblasts in the outer, adventitial layer, smooth muscle cells (SMCs) in the medial layer, and a monolayer of endothelial cells (ECs) in the intimal layer. Credit: Duke University

Biomedical engineers at Duke University have developed a three-layer model of human blood vessels that enables researchers to better understand how Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder that causes accelerated aging, affects the vascular system.

By combining three major types of cells found in blood vessel walls, this new model allows researchers to more comprehensively study how certain cells are affected by HGPS and explore how they respond to new therapies. The work is published in Science Advances.

HGPS is an extremely rare, fatal disease that causes accelerated aging in children. The condition is triggered by a random gene mutation, and children with it typically die in their teens or early 20s, often from cardiovascular complications like heart disease or stroke. But these complications don't arise from the typical drivers of cardiovascular disease, such as high cholesterol and the subsequent formation of artery-clogging plaques. Instead, blood vessels in people with HGPS undergo major structural changes, including the loss of smooth muscle cells and increased stiffness.

Adding fibroblasts to the vessel model

To better understand how and why these changes were occurring in HGPS, George Truskey, the R. Eugene and Susie E. Goodson distinguished professor of biomedical engineering, and Kevin Shores, a recent Ph.D. graduate from the Truskey lab, built on an earlier tissue-engineered blood vessel model containing endothelial and smooth muscle cells by adding a third cell layer made from fibroblasts.

Blood vessels are made up of several layers, each containing different cell types that work together to maintain the vessel's structure and function. Endothelial cells line the inside of the vessel and interact directly with the blood. Smooth muscle cells sit beneath them and help control the vessel's structure and contraction. Fibroblasts reside in the outer layer, where they help maintain the structure surrounding the vessel. These cells become more active when a blood vessel is injured or diseased, but their specific role in vascular disease has been difficult to study.

"Fibroblasts have traditionally been somewhat overlooked," said Truskey. "They're on the outside of the blood vessel, but they can influence what happens to the smooth muscle cells and the extracellular matrix. Most models have focused on the endothelial cells and the smooth muscle cells, but adding fibroblasts gives us a much better understanding of how the different cells can contribute to the disease."

Distinct cells drive different vascular changes

To determine which cell types were responsible for the vascular changes seen in HGPS, the researchers created models containing different combinations of healthy and HGPS cells.

"An advantage of our model is that we can easily mix and match cells that are expressing the disease-causing mutation with those that are not," said Shores. "This allowed us to get a better understanding of how each cell type was specifically contributing to the vascular pathology. We could also see if there were any synergistic effects between the different diseased cell types."

The approach revealed that different cell types appear to contribute to different aspects of the disease. For example, smooth muscle cells contributed to an accumulation of collagen, an important structural protein that normally helps give blood vessels strength and flexibility. But excessive collagen can alter the structure and mechanical properties of the vessel wall, making it thicker and stiffer and reducing its ability to expand and contract normally.

Endothelial cells, meanwhile, contributed to inflammation. While inflammation itself is a normal part of the body's response to injury, persistent inflammation can damage the vessel wall and trigger additional structural changes.

But most notably, the team saw that fibroblasts with the HGPS mutation substantially increased several features of vascular disease, including changes to the extracellular matrix, which affected the vessel's mechanical properties, and increased fibrotic signaling, which contributed to vessel stiffness.

"We could see how the interactions between cells shaped how the disease progresses," said Truskey. "It showed us we could gain valuable insights into the disease using this model."

Testing mutation correction in human cells

But the team didn't just use the model to explore disease progression—they also used it to investigate what happened when the mutation associated with HGPS was corrected.

Working with David Liu, the Thomas Dudley Cabot professor of the natural sciences at Harvard University and a Howard Hughes Medical Institute investigator, the team used CRISPR to correct the mutation in HGPS cells.

"Earlier studies showed results in mice, but we wanted to determine how correcting the mutation affected human vascular cells," said Truskey. "We found that when the mutation was corrected, many of the disease characteristics in the engineered blood vessels returned toward levels seen in healthy vessels."

"Developing new therapies for HGPS can be challenging because of its rarity and the nature of the disease. It's difficult to recruit a sufficient number of patients for clinical trials, and determining a treatment's effectiveness can take years," Shores said.

"Some past HGPS therapies that showed promise in animal models were ultimately found to be ineffective in patients. We think our model could be used, together with animal testing, to determine the most promising candidates to move forward with into clinical trials, hopefully decreasing the likelihood a therapy fails in patients."

Publication details

Kevin L. Shores et al, Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria, Science Advances (2026). DOI: 10.1126/sciadv.aeh3785

Journal information: Science Advances

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Lab-grown blood vessels reveal roles of different cells in rapid-aging disease (2026, October 9) retrieved 9 October 2026 from https://medicalxpress.com/news/2026-10-lab-grown-blood-vessels-reveal.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com